Zimmer L, McDade C, Beyhaghi H, Purser M, Textoris J, Krause A, Blanc E, Pavlov V, Earnshaw S. Cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury in the French healthcare setting. J Neurotrauma. 2023 Apr;40(7-8):706-19. doi: 10.1089/neu.2022.0270
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Pijuan-Domenech A, Pineda V, Ferreira-Gonzalez I, Marsal JR, Castro Miguel A, Sureda-Barbosa C, Valente F, Miranda B, Subirana-Domenech T, Dos-Subira L, Garcia-Dorado D, Casaldaliga-Ferrer J. Diagnosing abnormal end-diastolic forward flow: new definition proposal based on healthy controls. IJC CHD. 2021 Aug;4:100140. doi: 10.1016/j.ijcchd.2021.100140
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Thijssen JJJ, Bregantini D. Costly sequential experimentation and project valuation with an application to health technology assessment. J Econ Dyn Control. 2017 Apr 1;77:202-29. doi: 10.1016/j.jedc.2017.01.016
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Estrada CA, Unterborn JN, Price J, Thompson D, Gibson L. Judging the effectiveness of clinical pathways for pneumonia: the role of risk adjustment. Eff Clin Pract. 2000 Sep 1;3(5):221-8.